Pavella Therapeutics Inc. (PVLA) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Pavella Therapeutics Inc. (PVLA:NASDAQ), powered by AI.

Current Price
$110.12
P/E Ratio
-29.7
Market Cap
1.2B
Sector
Healthcare
What is the Pavella Therapeutics Inc. stock price forecast?

Pavella Therapeutics Inc. is currently trading at $110.12. View real-time AI analysis on Alpha Lenz.

What is Pavella Therapeutics Inc. insider trading activity?

View the latest insider trading data for Pavella Therapeutics Inc. on Alpha Lenz.

What is Pavella Therapeutics Inc.'s P/E ratio?

Pavella Therapeutics Inc.'s P/E ratio is -29.7.

Pavella Therapeutics Inc.

NASDAQ · PVLA
$110.12-6.39(-5.48%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Pavella Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Pavella Therapeutics Inc. trades at a P/E of -29.7 (undervalued) with modest ROE of -92.1%.

Ask for details

Company Overview

Pavella Therapeutics Inc. is a biotechnology company focused on developing innovative therapies for rare genetic disorders. The primary function of the company is to research and advance treatments that address unmet medical needs in the realm of genetic diseases, leveraging advanced biotechnological innovations. The company plays a significant role in the health care and pharmaceutical sectors, differentiating itself with its commitment to precision medicine approaches and personalized therapies. By concentrating on niche areas that are often overlooked by larger pharmaceutical firms, Pavella Therapeutics Inc. aims to provide hope and potential treatment options to patients with limited alternatives. In the financial markets, Pavella Therapeutics holds a distinctive position as a cutting-edge firm with the potential to drive significant impacts within its specialized domain. The company's activities contribute to the broader biotechnology landscape by enhancing understanding of genetic conditions and supporting the development of targeted biotherapeutic solutions.

CEOMr. Wesley H. Kaupinen
SectorHealthcare
IndustryBiotechnology
Employees14

Company Statistics

FY 2025

Profile

$1.24BMarket Cap
$0.00Revenue
0.00Shares Out
14Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-29.70P/E
44.28P/B
N/AEV/Sales
-33.49EV/EBITDA
-49.55P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-56.45%ROA
-92.10%ROE
-48.58%ROIC

Financial Health

$57.98MCash & Cash Equivalents
$-26.41MNet Debt
112.84%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Pavella Therapeutics Inc. (ticker: PVLA) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 14 employees. Market cap is $1.2B.

The current price is $110.12 with a P/E ratio of -29.7x and P/B of 44.28x.

ROE is -92.10%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Pavella Therapeutics Inc. (PVLA) Stock Forecast 2026 $110.12 — Price, Financials & Analyst Targets | Alpha Lenz